RESEARCH TRIANGLE PARK — Iqvia announced Wednesday that research showed that the benefits of therapies were consistent in both clinical trials and real world settings.
Iqvia participated in a study with Friends of Cancer Research, which works show the application of real world evidence in oncology research.
As part of the project, six research centers assessed cancer patients on a number of practical measures such as time between treatments and progression-free survival.
“While randomized clinical trials are the gold standard to evaluate whether a medical treatment can work, they don’t determine if treatment works for diverse patients outside the clinical setting and within real world situations,” said Nancy Dreyer, chief scientific officer for IQVIA Real World Solutions.
“This important study demonstrates the value of real world evidence to measure and quantify the comparative benefits and risks of various medical products.”
The study shows the benefit of real world data to support decision-making by regulatory agencies and healthcare payers, IQVIA said in a press release.
“These findings demonstrate that real-world end points are generally consistent with each other and with outcomes observed in randomized clinical trials, which substantiates the potential validity of real-world data to support regulatory and payer decision making,” the conclusion of the study notes.
“Differences observed likely reflect true differences between real-world and protocol-driven practices.”
The full study can be read online.
IQVIA is a health information technology and clinical research company. Shares of their stock were trading at $152.16 Wednesday, down 78 cents.
(C) North Carolina Business News Wire
